Prophylaxis of Venous Thrombo-Embolism in Cancer Patients Under Palliative Care

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Study Classification

OBSERVATIONAL

Study Start Date

2001-01-31

Study Completion Date

2002-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To determine the efficacy and to measure the complications of prophylactic anticoagulation using low-molecular weight heparin in adult cancer patients under palliative care

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cancer Venous Thromboembolism

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

DEFINED_POPULATION

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

nadroparin

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Cancer patients in palliative care
* Patients fully informed about their condition
* Signed informed consent

Exclusion Criteria

* Absence of advanced cancer
* Cancer previously cured
* Venous thromboembolism diagnosed within 6 months prior to inclusion
* Absence of discerning capacity
* Active anti-thrombotic treatment with heparins or coumarines
* Thrombocytopenia \<50G/l
* PTT \>45sec
* TP\<35%
* Active bleeding
* Renal failure \<20ml/min
* Past history of heparin-induced thrombocytopenia

Minimum Eligible Age

0 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Catherine Weber, MD

Role: PRINCIPAL_INVESTIGATOR

Center of Continuous Care, chemin de la Savonnière 11, CH-1245 Collonge-Bellerive

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Center of Continuous Care, chemin de la Savonnière

Collonge-Bellerive (Geneva), Canton of Geneva, Switzerland

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Switzerland

References

Explore related publications, articles, or registry entries linked to this study.

Prandoni P. Antithrombotic strategies in patients with cancer. Thromb Haemost. 1997 Jul;78(1):141-4.

Reference Type BACKGROUND

PMID: 9198144 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

SPOT 99/54

Identifier Type: -

Identifier Source: org_study_id